肝硬化患者合并曲霉菌感染患者

Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,Click to edit Master title style,*,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,Click to edit Master title style,*,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,Click to edit Master title style,*,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,Click to edit Master title style,*,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,Click to edit Master title style,*,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,Click to edit Master title style,*,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,Click to edit Master title style,*,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,Click to edit Master title style,*,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,Click to edit Master title style,*,单击此处编辑母版标题样式,单击此处编辑母版文本样式,第二级,第三级,第四级,第五级,*,*,单击此处编辑母版标题样式,单击此处编辑母版文本样式,第二级,第三级,第四级,第五级,*,*,文献阅读报告,重度肝硬化合并曲霉菌感染患者使用,伏立康唑剂量的调整,患者男，,56,岁，身高,176cm,，体质量,100kg,，因,HBsAg,阳性,6,年，乏,力、尿黄,1,月余，发热伴咯血,3,天入院。检查提示：,ALT,2,18U,L,，,AST,1,67U,L,，总胆红素,409mol/L,。双肺,CT,平扫：双肺多发大小不,等类圆形高密度影，其内可见空洞。,临床诊断：,1,、乙型病毒性肝炎、肝炎肝硬化；,2,、急性肝功能衰,竭；,3,肺部感染；,4,慢性肾功能不全。,给予护肝、降酶、退黄、哌拉西林他唑巴坦抗感染治疗、免疫等,对症治疗。住院期间,2,次痰培养均为烟曲霉菌，给予卡泊芬净治疗,1,周后患者咳痰增多，发热，最高达,39,2,。外院专家会诊建议,加用伏立康唑治疗。,能不能用？剂量是否需要调整？,肝功能损害者用药,急性肝损害者（,ALT,、,AST,增高）：无需调整剂量，但监测肝功能。,轻度到中度肝硬化患者（,Child-Pugh A,和,B,）：建议伏立康唑的负,荷剂量（,6mg/kg,）不变，但维持剂量减半。,重度肝硬化者（,Child-Pugh C,）：目前尚无研究。,ABX指南肝功能受损时剂量：轻中度肝功能不全：6mg/kg q12h(负荷量)，其后2mg/kg iv q12h，监测血药浓度。,抗微生物治疗指南（热病41版）IV:6mg/kg q12h治疗侵袭性曲霉菌病和严重霉菌感染：4mg/kg,q12h,有中度肝脏损伤者，维持剂量减半。,伏立康唑,说明书,伏立康唑相关,指南,检索文献,检索工具,：,数据库：,CNKI,、,Pubmed,检索途径：高级检索,关键检索词：伏立康唑、肝功能异常 （,Voriconazolen,、,Liver Cirrhosis,、,severe liver dysfunction,）,检索时间：,2005-201,7年,检索结果,：中文文献（,38,篇）、英文文献（,24,篇）,文献筛选原则,：研究内容的有效性、文献类型（系统评,价或,meta,分析、,RCT,、综述等）、新颖度、质量等,文献筛选结果,：,4,篇,Altered Pharmacokinetics of Voriconazolen a Patient with Liver Cirrhosis,A 45-year-old male(,body weight,100 kg,),Fatty-liver cirrhosis(,Child-Pugh class C,;model of end-stage liver disease score,20)who was listed for liver transplantation and showed signs of,portal hypertension,(esophageal varices and ascites)and cholestasis(plasma bilirubin level,20.26 mg/dl,or 346 mol/liter),Received,2 mg of VRC/kg,of body weight orally,twice a day,because of suspected pulmonary aspergillosis.,At,day 30,of clinical treatment with VRC,he was transferred to the ICU because of unconsciousness(Glasgow Coma Scale score,5 of 15)and hyperventilation.,文献,1,：,肝硬化患者使用伏立康唑的药代动力学变化,半衰期：4.7h,53.1h,清除率：253.9 1.4mg/h/kg,文献,1,：,肝硬化患者使用伏立康唑的药代动力学变化,伏立康唑,80%,经肾脏排泄，,20%,经胆汁消除。,高浓度的伏立康唑呈现非线性动力学，半衰期延长。,conclusions,：,In patients with,moderate liver cirrhosis(Child-Pugh class B),a,reduction of the maintenance dose by,50%,is recommended for patients with mild to moderate hepatic insufficiency,.,For patients with,severely impaired liver function,a dose reduction of more than 50%,appears to be required,and,therapeutic drug monitoring,will greatly improve therapeutic safety.,对于重度肝功能损伤的患者，伏立康唑维持剂量减少,超过50%是必须的，应该进行治疗药物检测。,文献,1,：,肝硬化患者使用伏立康唑的药代动力学变化,Between 1999 and 2009,we screened all adult patients,admitted to the Liver Intensive Therapy Unit(LITU)at,Kings College Hospital in London and identified patients,who had a Model for End Stage Liver Disease(MELD),greater than 9 and had received at least 4 doses of voriconazole.,文献,2,：,伏立康唑在严重肝功能障碍患者的肝毒性,文献,2,：,伏立康唑在严重肝功能障碍患者的肝毒性,给予负荷剂量的患者有,13,人（,44.8%,），其余,16,人直接给予治疗剂量。,平均负荷剂量：,30245.9mg/day or 4.60.7mg/kg/day(200-400mg/day;3.3-5.5mg/kg/day),治疗剂量：,218.641.4mg/day or 3.630.7mg/kg/day(160-300mg/day;2.58-4.33mg/kg/day),给药次数：,25,人为,Qd,，,4,人为,Bid,平均治疗天数：,39.751.7days,（,5-180days,）,文献,2,：,伏立康唑在严重肝功能障碍患者的肝毒性,文献,2,：,伏立康唑在严重肝功能障碍患者的肝毒性,69%,of patients treated with voriconazole showed changes in liver functiontests(LFTs)during therapy.The control group developed alterations in the LFTs in only,10.3%,of patients.,They showed elevated transaminases in,35%,cholestasis in,15%,or a combination of both in,45%,.According to the CTC classification,all patients with hepatotoxicity had a severe reaction.,There was,a correlation between initial loading dose greater than 300 mg(4.5 mg/kg)and the risk of hepatotoxicity,(p 0.001).,Voriconazole hepatotoxicity in severe liver Dysfunction.Journal of Infection(2013)66,80-86,文献,2,：,伏立康唑在严重肝功能障碍患者的肝毒性,文献,3,伏立康唑联合卡泊芬净成功治疗2例肝功能衰竭,合并侵袭性肺曲霉菌病,说明卡泊芬净与伏立康唑联用有一定的协同作用,Li D,，,Chert L,，,Ding X,，,et a1,Hospital,acquired invasive pulmonary aspergillosis in patients with hepatic failureJ,BMC Gastroenterol,，,2008,，,31,：,32,本研究中,2,例患者均采用了伏立康唑,+,卡泊芬净静脉应用和两性霉素,B,脂质体雾化吸入的三联抗曲霉菌治疗，未出现因药物因素导致的肝功能和,(,或,),肾功能进一步加重的表现，耐受性较好，并于联合用药后感染得到控制并逐渐好转。,2007年病例，酒精性肝硬化患者（child c）给予剂量为,负荷剂量4